Project Grant R13CA250298

The National Cancer Institute awarded a $244,228 Project Grant to the University of Texas MD Anderson Cancer Center to develop a proteomics-driven approach to accurately map patient tumor samples to preclinical models in lung cancer research under the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394). The goal is to expand proteomic profiling of lung cancer patient-derived xenograft (PDX) models using reverse-phase protein arrays (RPPAs) to build a comprehensive...

Grant Award Summary Cold Spring Harbor Laboratory received a $704,182 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on June 16, 2026, with completion targeted for May 31, 2031. The grant funds fundamental research to elucidate the non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer (CRC). The research utilizes an innovative mouse model that replicates the stepwise acquisition of...

Cooperative Agreement Summary The National Cancer Institute awarded Mayo Clinic Arizona a $1.41 million Cooperative Agreement on August 15, 2025, under the Cancer Biology Research program (CFDA 93.396) to conduct preclinical studies for the immunoprevention of multiple myeloma, with performance completion targeted for May 31, 2027. The award funds development and utilization of clinically predictive, immunocompetent mouse models—specifically the VKMYC and VKMYCHCRBN strains—to study the...

This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...

This Project Grant award for $399,187 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support Virginia Commonwealth University's research to develop novel genetically engineered mouse models to study the development of marginal zone lymphomas (MZL). The research aims to 1) investigate the impact of activation of the PI3K/AKT/mTOR pathway on MZL development, and 2) determine optimal drug combinations for targeting this pathway in MZL. This work seeks to establish...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $156,000 to The Regents of the University of Colorado (University of Colorado-Denver) under the Cancer Biology Research program (CFDA 93.396) for a two-year project period spanning April 1, 2026, through March 31, 2028. The award funds optimization of preclinical research models for adamantinomatous craniopharyngioma (ACP), a rare and highly morbid pediatric brain tumor. The primary deliverables include refinement...

Award Summary The National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded a three-year, $450,000 Cooperative Agreement to the University of California, Santa Cruz, effective May 1, 2026, through April 30, 2029. The project, "Pangenome-Aware Methods for Accurate Somatic Variant Discovery in Cancer Genomics," addresses critical challenges in detecting somatic mutations in cancer genomes by leveraging pangenome reference approaches and long-read...

The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived tumor...

The National Cancer Institute (NCI) awarded a $415,257 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Methodist Hospital Research Institute (HMRI) in Houston, TX to develop a pre-clinical syngeneic pig glioma model for research and translational studies related to glioblastoma (GBM). The project aims to establish a large animal glioma model that can recapitulate key features of human GBM, which is a uniformly fatal brain cancer with poor prognosis. The model will be used to study...

Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $681,310 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on June 24, 2026, under the Cancer Biology Research program (CFDA 93.396). The award supports research investigating the mechanisms of bone metastasis and tumor dormancy in prostate cancer through June 2031. Columbia University will develop and utilize genetically-engineered mouse...